TheraRadar
Data updated: May 26, 2026

TELMISARTAN AND AMLODIPINE (amlodipine besylate)

Cardiovascular Approved 2014-01-08
Jump to: Indications Approvals Trials Competitors Safety Patents
3
Indications
--
Phase 3 Trials
12
Years on Market

Details

Status
Discontinued
First Approved
2014-01-08
Routes
ORAL
Dosage Forms
TABLET

Companies

Lupin ALEMBIC Viatris TORRENT
Active Ingredient: AMLODIPINE BESYLATE , TELMISARTAN

TELMISARTAN AND AMLODIPINE Approval History

2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Original
New Indication
New Form
Label Update
60 FDA actions from 2014 to 2021
Oct 2021 SUPPL
Label · Labeling
Sep 2019 SUPPL
Label · Labeling
May 2019 SUPPL
Label · Labeling

What TELMISARTAN AND AMLODIPINE Treats

3 FDA approvals

Originally approved for its first indication in 2014 . Covers 3 distinct patient populations.

  • Other (3)
📋

Clinical Trial Registry

10 trials
Trial Sponsor ID Phase Status Title
NCT04434664 BLOCK HFpEF results posted 833517 Ph 4 completed BLOCKade of Calcium Channels and Beta Adrenergic Receptors for the Treatment of Hypertension in HFpEF
NCT04974138 CSPPT2-CC/CT CSPPT2-CC/CT_2020 Ph 4 recruiting China Stroke Primary Prevention Trial 2 for Participants With H-type Hypertension and MTHFR 677 CC/CT Genotype (CSPPT2-CC/CT)
NCT04974151 CSPPT2-TT CSPPT2-TT_2020 Ph 4 recruiting China Stroke Primary Prevention Trial 2 for Participants With Hypertension and MTHFR 677 TT Genotype
NCT05275907 STU00215781 1R56HL155093-01 Ph 4 withdrawn Mechanism of Hypertension Treatments in Liver Transplant Recipients (BLOCK LTR-HTN)
NCT02940548 NARRAS 2016PHB013-02 Ph 4 terminated Nifedipine GITS and Amlodipine Besylate on Recovery of Blood Pressure Rhythm and Arterial Stiffness
NCT01302691 results posted 0954E-357 Ph 3 completed MK-0954E Study in Participants With Hypertension (MK-0954E-357)
NCT02353806 results posted 042014-059 UL1TR001105 Ph 4 completed Pharmacokinetics of Amlodipine Besylate at Delivery and During Lactation
NCT01556997 PATH results posted X985400 Ph 3 completed Perindopril Amlodipine for the Treatment of Hypertension
NCT01222520 results posted 1235.36 Ph 3 completed Telmisartan 80mg Non-responder Trial
NCT00860262 results posted 1235.20 2008-000873-40 Ph 3 completed Telmisartan and Amlodipine Fixed Dose Combination [FDC] Trial for the Treatment of Severe Hypertension
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...
⭐

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

ClinicalTrials.gov ↗ Pro

Full development history with FDA approval milestones

|
Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

TELMISARTAN AND AMLODIPINE FDA Label Details

Track TELMISARTAN AND AMLODIPINE with TheraRadar Pro

Watchlist alerts, full database access, CSV exports across 14,000+ drugs.

Upgrade to Pro

Data Sources

FDA Approval: ANDA201586 → Trials: ClinicalTrials.gov →

Data sourced from official FDA and NIH databases. Click links to verify on original sources.